Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 13, 2013

Primary Completion Date

April 4, 2016

Study Completion Date

April 4, 2016

Conditions
Ischemic StrokeMalignant Edema
Interventions
DRUG

Glyburide for Injection

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Trial Locations (17)

15213

UPMC Presbyterian Hospital, Pittsburgh

19001

Abington Memorial Hospital, Abington

21201

University of Maryland School of Medicine, Baltimore

29425

Medical University of South Carolina, Charleston

32209

University of Florida, Jacksonville, Jacksonville

40202

University of Louisville Hospital, Louisville

43210

Ohio State University Wexner Medical Center, Columbus

44195

Cleveland Clinic, Cleveland

60611

Northwestern Memorial Hospital, Chicago

84132

University of Utah Healthcare, Salt Lake City

85719

University of Arizona Medical Center, Tucson

94305

Stanford University Medical Center, Stanford

97239

Oregon Health & Science University Hospital, Portland

06510

Yale University School of Medicine, New Haven

04074

Maine Medical Center, Scarborough

02114

Massachusetts General Hospital, Boston

01655

UMASS Memorial Medical Center, Worcester

All Listed Sponsors
lead

Remedy Pharmaceuticals, Inc.

INDUSTRY

NCT01794182 - Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals | Biotech Hunter | Biotech Hunter